The Effects of NAD on Brain Function and Cognition
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 4
- 主要终点
- Change in Cognitive Assessment - Montreal Cognitive Assessment (MoCA) - from baseline at 10 weeks
研究概览
简要总结
The purpose of this study is to determine the effects of Niagen (nicotinamide riboside, vitamin B3), on NAD levels, brain function including cognition and blood flow in people diagnosed with mild cognitive impairment (MCI).
详细描述
Niagen is a patented formula which is the first and only commercially available form of Nicotinamide Riboside (NR). It has been proven in basic science studies as a highly effective NAD booster, but it also works as a vitamin B3 supplement. NAD helps pass energy from glucose to other pathways in the cell. Niagen (Nicotinamide Riboside, vitamin B3) is one of the most effective NAD+ precursors to support cellular health.
The purpose of this study is to determine the effects of Niagen (nicotinamide riboside, vitamin B3), on NAD levels, brain function including cognition and blood flow in people diagnosed with mild cognitive impairment (MCI).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Previously diagnosed with MCI based on inclusion criteria of Texas Alzheimer's Research Care and Consortium (TARCC) study (IRB: HSC20090535H). We are enrolling both genders, all races and ethnic groups.
- •Two week washout period for participants who were taking opioids or a dose of niacin over 200mg
排除标准
- •Previously considered as healthy individuals without a MCI or Alzheimer's disease diagnosis based on exclusion criteria of the TARCC study (IRB: HSC20090535H).
- •Neurological, psychiatric or active systemic medical disease
- •Moderate or severe depression and/or anxiety as determined the Geriatric Depression Scale (GDS) and the Geriatric Anxiety Scale (GAS), respectively
- •Diagnosis of dementia
- •Hearing, vision, motor or language deficits
- •Alcohol or drug abuse
- •Implantation of metal devices
- •Administration of Alzheimer's drugs, anticholinergics, neuroleptics, anticonvulsants, opiates, systemic steroids, and mood-stabilizers.
- •No opioid use while participating in study
结局指标
主要结局
Change in Cognitive Assessment - Montreal Cognitive Assessment (MoCA) - from baseline at 10 weeks
时间窗: 10 weeks
MoCA Value
次要结局
- Change in endothelial function from baseline at 10 weeks(10 weeks)
- Change in Cognitive Assessment - Test of Auditory Processing Skills (TAPS) - from baseline at 10 weeks(10 weeks)
- Change in Physical Performance - Short Physical Performance Battery (SPPB) - from baseline at 10 weeks(10 weeks)
- Change in cerebral blood flow from baseline at 10 weeks(10 weeks)
- Change in plasma NAD from baseline at 10 weeks(10 weeks)
- Change in Physical Performance - Instrumental Activities of Daily Living (IADLs) - from baseline at 10 weeks(10 weeks)
- Change in Cognitive Assessment - Geriatric Depression Scale (GDS) - from baseline at 10 weeks(10 weeks)
- Change in Cognitive Assessment - Geriatric Anxiety Scale (GAS) - from baseline at 10 weeks(10 weeks)
- Change in Cognitive Assessment - Clock Drawing Task Protocol (CLOX) - from baseline at 10 weeks(10 weeks)
- Change in Cognitive Assessment - Executive Interview (EXIT) - from baseline at 10 weeks(10 weeks)
- Change in Physical Performance - Grip Strength - from baseline at 10 weeks(10 weeks)